Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma
Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL-2) and programmed death-ligand 1 inhibition may improve eff...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2023
|
| In: |
Clinical lymphoma, myeloma & leukemia
Year: 2023, Jahrgang: 23, Heft: 1, Pages: e59-e70 |
| ISSN: | 2152-2669 |
| DOI: | 10.1016/j.clml.2022.10.006 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clml.2022.10.006 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2152265022017128 
|
| Verfasserangaben: | Fredrik Schjesvold, Bruno Paiva, Vincent Ribrag, Paula Rodriguez-Otero, Jesus F. San-Miguel, Pawel Robak, Markus Hansson, Maika Onishi, Habib Hamidi, Vikram Malhi, Monique Dail, Apurva Javery, Grace Ku, Marc S. Raab |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1833389417 | ||
| 003 | DE-627 | ||
| 005 | 20230706221323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230207s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2022.10.006 |2 doi | |
| 035 | |a (DE-627)1833389417 | ||
| 035 | |a (DE-599)KXP1833389417 | ||
| 035 | |a (OCoLC)1389533334 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schjesvold, Fredrik |e VerfasserIn |0 (DE-588)1208033425 |0 (DE-627)1694343219 |4 aut | |
| 245 | 1 | 0 | |a Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma |c Fredrik Schjesvold, Bruno Paiva, Vincent Ribrag, Paula Rodriguez-Otero, Jesus F. San-Miguel, Pawel Robak, Markus Hansson, Maika Onishi, Habib Hamidi, Vikram Malhi, Monique Dail, Apurva Javery, Grace Ku, Marc S. Raab |
| 264 | 1 | |c 2023 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht am 22. Oktober 2022, Dateiversion vom 16. Dezember 2022 | ||
| 500 | |a Gesehen am 07.02.2023 | ||
| 520 | |a Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL-2) and programmed death-ligand 1 inhibition may improve efficacy. This phase Ib/II trial (NCT03312530) evaluated safety and efficacy of cobimetinib (cobi) alone and in combination with venetoclax (ven) with/without atezolizumab (atezo) in patients with R/R MM. | ||
| 650 | 4 | |a B-cell lymphoma-2, Programmed death-ligand 1 | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Mitogen-activated protein kinase pathway, Immunotherapy | |
| 700 | 1 | |a Paiva, Bruno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ribrag, Vincent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rodriguez-Otero, Paula |e VerfasserIn |4 aut | |
| 700 | 1 | |a San-Miguel, Jesus F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Robak, Pawel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hansson, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Onishi, Maika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamidi, Habib |e VerfasserIn |4 aut | |
| 700 | 1 | |a Malhi, Vikram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dail, Monique |e VerfasserIn |4 aut | |
| 700 | 1 | |a Javery, Apurva |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ku, Grace |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d Amsterdam [u.a.] : Elsevier, 2010 |g 23(2023), 1 vom: Jan., Seite e59-e70 |h Online-Ressource |w (DE-627)620142014 |w (DE-600)2540998-0 |w (DE-576)358408776 |x 2152-2669 |7 nnas |a Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g month:01 |g pages:e59-e70 |g extent:12 |a Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clml.2022.10.006 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2152265022017128 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230207 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 14 |y j | ||
| 999 | |a KXP-PPN1833389417 |e 4268230580 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Fredrik","role":"aut","family":"Schjesvold","display":"Schjesvold, Fredrik"},{"family":"Paiva","display":"Paiva, Bruno","given":"Bruno","role":"aut"},{"display":"Ribrag, Vincent","family":"Ribrag","role":"aut","given":"Vincent"},{"given":"Paula","role":"aut","display":"Rodriguez-Otero, Paula","family":"Rodriguez-Otero"},{"given":"Jesus F.","role":"aut","display":"San-Miguel, Jesus F.","family":"San-Miguel"},{"role":"aut","given":"Pawel","family":"Robak","display":"Robak, Pawel"},{"display":"Hansson, Markus","family":"Hansson","given":"Markus","role":"aut"},{"given":"Maika","role":"aut","family":"Onishi","display":"Onishi, Maika"},{"display":"Hamidi, Habib","family":"Hamidi","role":"aut","given":"Habib"},{"family":"Malhi","display":"Malhi, Vikram","role":"aut","given":"Vikram"},{"role":"aut","given":"Monique","family":"Dail","display":"Dail, Monique"},{"family":"Javery","display":"Javery, Apurva","role":"aut","given":"Apurva"},{"given":"Grace","role":"aut","family":"Ku","display":"Ku, Grace"},{"family":"Raab","display":"Raab, Marc-Steffen","role":"aut","given":"Marc-Steffen"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma","title_sort":"Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma"}],"origin":[{"dateIssuedDisp":"2023","dateIssuedKey":"2023"}],"note":["Online veröffentlicht am 22. Oktober 2022, Dateiversion vom 16. Dezember 2022","Gesehen am 07.02.2023"],"id":{"eki":["1833389417"],"doi":["10.1016/j.clml.2022.10.006"]},"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Fredrik Schjesvold, Bruno Paiva, Vincent Ribrag, Paula Rodriguez-Otero, Jesus F. San-Miguel, Pawel Robak, Markus Hansson, Maika Onishi, Habib Hamidi, Vikram Malhi, Monique Dail, Apurva Javery, Grace Ku, Marc S. Raab"]},"relHost":[{"language":["eng"],"part":{"volume":"23","extent":"12","text":"23(2023), 1 vom: Jan., Seite e59-e70","issue":"1","pages":"e59-e70","year":"2023"},"titleAlt":[{"title":"Clinical lymphoma, myeloma and leukemia"}],"pubHistory":["10.2010 -"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dallas, Tex.","dateIssuedDisp":"2010-","publisher":"Elsevier ; CIG Media Group","dateIssuedKey":"2010"}],"note":["Gesehen am 04.02.20"],"title":[{"title_sort":"Clinical lymphoma, myeloma & leukemia","title":"Clinical lymphoma, myeloma & leukemia"}],"disp":"Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myelomaClinical lymphoma, myeloma & leukemia","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"620142014","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["620142014"],"zdb":["2540998-0"],"issn":["2152-2669"]}}],"recId":"1833389417"} | ||
| SRT | |a SCHJESVOLDCOBIMETINI2023 | ||